U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06972693) titled 'NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma' on Jan. 07.
Brief Summary: For patients with ovarian cancer and biologically related diseases, the implementation of genetic testing in the decision-making process could have an impact both on the risk management for the patient and his/her family, but also, more importantly, on the therapeutic management.
The identification of genetically predisposed subjects can suggest risk reduction strategies that may involve bilateral salpingo-oophorectomy, mastectomy or long-term medical approaches. In the advanced setting, genetic testing may influence the decision for medical...